AZN And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial

(RTTNews) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival ( https://www.nasdaq.com/articles/azn-and-daiichi-sankyos-enhertu-shows-significant-survival-benefit-phase-3-gastric-cancer